These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 2677243)

  • 1. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
    Norman TR; Burrows GD
    J Neural Transm Suppl; 1989; 28():53-63. PubMed ID: 2677243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible monoamine oxidase-A inhibitors in panic disorder.
    Bakish D; Saxena BM; Bowen R; D'Souza J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of MAO inhibitors: safety and future.
    Yamada M; Yasuhara H
    Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
    Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
    J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
    Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
    Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
    Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of panic disorder: brief review.
    Liebowitz MR
    Psychopharmacol Bull; 1989; 25(1):17-20. PubMed ID: 2672068
    [No Abstract]   [Full Text] [Related]  

  • 10. Monoamine oxidase inhibitors and alprazolam in the treatment of panic disorder and agoraphobia.
    Sheehan DV
    Psychiatr Clin North Am; 1985 Mar; 8(1):49-62. PubMed ID: 2859580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential response patterns to MAO inhibitors and tricyclics.
    Nies A
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):70-7. PubMed ID: 6376487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of some anxiogenic agents on rat brain monoamine oxidase (MAO) A and B inhibitory (tribulin) activity.
    Bhattacharya SK; Chakrabarti A; Sandler M; Glover V
    Indian J Exp Biol; 1996 Dec; 34(12):1190-3. PubMed ID: 9246908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tribulin and endogenous MAO-inhibitory regulation in vivo.
    Medvedev AE; Glover V
    Neurotoxicology; 2004 Jan; 25(1-2):185-92. PubMed ID: 14697893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.
    Chiuccariello L; Cooke RG; Miler L; Levitan RD; Baker GB; Kish SJ; Kolla NJ; Rusjan PM; Houle S; Wilson AA; Meyer JH
    Int J Neuropsychopharmacol; 2015 Aug; 19(1):. PubMed ID: 26316187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder.
    Westenberg HG; den Boer JA
    Psychopharmacol Bull; 1989; 25(1):119-23. PubMed ID: 2528158
    [No Abstract]   [Full Text] [Related]  

  • 16. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
    Naoi M; Riederer P; Maruyama W
    J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL; Page RL; Ruscin JM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.
    Liebowitz MR; Hollander E; Schneier F; Campeas R; Welkowitz L; Hatterer J; Fallon B
    Acta Psychiatr Scand Suppl; 1990; 360():29-34. PubMed ID: 2248064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute cardiovascular response to monoamine oxidase inhibitors: a prospective assessment.
    Keck PE; Vuckovic A; Pope HG; Nierenberg AA; Gribble GW; White K
    J Clin Psychopharmacol; 1989 Jun; 9(3):203-6. PubMed ID: 2738182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.